|
|
|
Company News
|
SIGA Technologies Reports Financial Results for the First Quarter 2013
SIGA Technologies
(May 15, 2013)
|
SIGA Announces Restatement of Certain Historical Financial Results to Reflect Reclassification of Warrants as a Liability
SIGA Technologies
(May 10, 2013)
|
Siga to Host First Quarter Business Update Call on May 6, 2013
SIGA Technologies
(April 30, 2013)
|
SIGA Delivers First Courses of Arestvyr(TM) Under BARDA Contract
SIGA Technologies
(March 12, 2013)
|
SIGA Technologies Reports Financial Results for the Fourth Quarter and Year Ended 2012
SIGA Technologies
(March 06, 2013)
|
SIGA to Host Fourth Quarter and Year End Business Update Call on March 6, 2013
SIGA Technologies
(March 01, 2013)
|
Weekly Market Movers (to 15 Feb 2013)
(February 18, 2013)
|
PharmAthene Announces Delaware Supreme Court Hears Oral Arguments In Its Litigation With SIGA Technologies
PharmAthene
(January 10, 2013)
|
ST-246(R) to be Branded Arestvyr(TM)
SIGA Technologies
(November 29, 2012)
|
SIGA Technologies Reports Financial Results for the Third Quarter of 2012
SIGA Technologies
(November 05, 2012)
|
|
|
|
|
EvaluatePharma® - the premier source for pharma and biotech analysis.
Expert integration of financial and product data across historic and forecast timeframes (1986 to 2018) delivers a vast array of analytics by product, company, therapy area, EphMRA ATC code, technology, patent status, deals, license revenues and much more.
|
|
Company Profile
|
| Profile
|
SIGA Technologies (SIGA) is a New York based pharmaceutical company focused on development of therapeutic solutions for some of the most lethal disease-causing pathogens – smallpox, Ebola, dengue, Lassa fever & other dangerous viruses. |
| Listed or Private Company
|
Listed |
| Company Classification
|
Biotechnology |
| Country
|
USA
|
| Company Website
|
Website
|
|
Full Company Profile Information
|
EventAnalyzer - Last Key Event
|
| Closing Price DateClosing Price Date
|
EventAnalyzer Note
|
Market Cap (US $m)
|
Change (%)
|
Change (+$m)
|
| 26/03/2012 |
26 Mar: Shares rise on 5.5x average daily trading volume. |
180 |
29.3% |
41 |
|
|
EvaluatePharma® Coverage of Marketed and Pipeline Products
|
|
|
|
Welcome
Evaluate provides market intelligence and analysis for the pharma, biotech and medtech industries.
Explore Evaluate
Partnering
EvaluatePharma® now includes Partnering Opportunities - products available for licensing.
Partnering Opportunities in EvaluatePharma® are sourced from the rights holders - all entries are verified by the team of Analysts at EvaluatePharma - and presented in their commercial context.
Register to submit your Partnering Opportunities or to see your own and other Partnering Opportunities in their commercial context with the unique industry-wide analysis in EvaluatePharma®.
Take a full subscription to see all products available for license, including updated contact details for the out-licensing entity.
Register to access more FREE content:
- 2011 Product Sales analysis
- 2011 Pharmaceutical Sales
- 2011 Market Share & Global Ranking
- Download to Excel
- Search 2 yrs of company press releases
Register for Free Analysis
Register to access more free insights and analysis from Evaluate.
Register Now
|
|
|
|